Based on these preliminary results, FASN drugs inhibitors should be used in the future, in association with standard chemotherapy, for the treatment of CRC patients; more so because CAAs exhibit the ability to metabolize chemotherapeutic drugs, thus contributing to their bioavailability decrease and to the chemotherapeutic resistance development. The gene discussed is FASN; the disease is colorectal carcinoma.